Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas Rex

Research output: Contribution to journalArticle

91 Scopus citations

Abstract

The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.

Original languageEnglish (US)
JournalGastroenterology
DOIs
StateAccepted/In press - 2016

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer'. Together they form a unique fingerprint.

  • Cite this

    Robertson, D. J., Lee, J. K., Boland, C. R., Dominitz, J. A., Giardiello, F. M., Johnson, D. A., Kaltenbach, T., Lieberman, D., Levin, T. R., & Rex, D. (Accepted/In press). Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. https://doi.org/10.1053/j.gastro.2016.08.053